



1 June 2023

**Proteome Sciences plc  
("Proteome Sciences" or the "Company")**

**Repayment of Loan to Vulpes Investment Management Private Limited**

The Directors of Proteome are pleased to announce that the Company has today repaid in full the outstanding loan and associated interest (together totalling £824,424) to Vulpes Investment Management Private Limited originally announced on 2 July 2018 and amended on 30 March 2022.

**Proteome Sciences plc**

Dr. Mariola Soehngen, Chief Executive Officer  
Dr. Ian Pike, Chief Scientific Officer  
Richard Dennis, Chief Commercial Officer  
Abdelghani Omari, Chief Financial Officer

Tel: +44 (0)20 7043 2116

**Allenby Capital Limited (Nominated Adviser & Broker)**

John Depasquale / Jeremy Porter (Corporate Finance)  
Tony Quirke / Stefano Aquilino (Equity Sales & Corporate Broking)

Tel: +44 (0) 20 3328 5656

**About Proteome Sciences plc. ([www.proteomics.com](http://www.proteomics.com))**

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.